Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Boston Scientific Corp Market Cap
Based on ratings from 24 stock analysts, the Boston Scientific Corp stock price is expected to increase by 2.06% in 12 months. This is calculated by using the average 12-month stock price forecast for Boston Scientific Corp. The lowest target is $78 and the highest is $100. Please note analyst price targets are not guaranteed and could be missed completely.
Boston Scientific Corp has a total of 24 Wall St Analyst ratings. There are 18 buy ratings, 6 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Boston Scientific Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of BSX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Shagun Singh RBC Capital | Outperform | $95 | Maintains | Oct 8, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $90 | Maintains | Oct 1, 2024 |
| Jayson Bedford Raymond James | Strong Buy | $94 | Maintains | Sep 4, 2024 |
| Matt Miksic Barclays | Overweight | $86 | Maintains | Aug 22, 2024 |
| Joanne Wuensch Citigroup | Buy | $92 | Maintains | Aug 22, 2024 |
| Robbie Marcus JP Morgan | Overweight | $85 | Maintains | Jul 25, 2024 |
| Jayson Bedford Raymond James | Strong Buy | $91 | Maintains | Jul 25, 2024 |
| Mike Matson Needham | Buy | $86 | Maintains | Jul 25, 2024 |
| Shagun Singh RBC Capital | Outperform | $85 | Reiterates | Jul 25, 2024 |
| Pito Chickering Deutsche Bank | Hold | $78 | Maintains | Jul 25, 2024 |
| William Plovanic Canaccord Genuity | Buy | $88 | Maintains | Jul 25, 2024 |
| David Rescott Baird | Outperform | $91 | Maintains | Jul 25, 2024 |
| Richard Newitter Truist Securities | Buy | $90 | Maintains | Jul 16, 2024 |
| Joshua Jennings TD Cowen | Buy | $86 | Maintains | Jul 16, 2024 |
| Marie Thibault BTIG | Buy | $84 | Maintains | Jul 15, 2024 |
| Patrick Wood Morgan Stanley | Overweight | $92 | Maintains | Jul 15, 2024 |
Citigroup | Buy | Maintains | Jul 11, 2024 | |
| Joanne Wuensch Citigroup | Buy | $90 | Maintains | Jul 10, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $81 | Maintains | Jul 2, 2024 |
| Mike Matson Needham | Buy | $82 | Reiterates | Jun 18, 2024 |
When did it IPO
1992
Staff Count
48,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Michael F. Mahoney
Market Cap
$126.94B
In 2023, BSX generated $14.24B in revenue, which was a increase of 12.29% from the previous year. This can be seen as a signal that BSX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 08 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analyst recommendations from brokerage firms can significantly impact stock prices, influencing investors' decisions to buy, sell, or hold.
Why It Matters - Analyst recommendations can significantly sway stock prices, impacting investor sentiment and trading volume, which can lead to volatility and potential investment opportunities.
Wed, 09 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have shown performance metrics relative to their sector in 2023. Further details on their specific performance were not provided.
Why It Matters - Performance comparisons highlight relative strength or weakness, influencing investment decisions and portfolio strategies based on sector trends and individual company outlooks.
Mon, 07 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Royal Caribbean Cruises, Boston Scientific, and Monolithic Power Systems are identified as top investment picks due to their high net income ratios.
Why It Matters - High net income ratios indicate strong profitability, making these stocks attractive for potential growth and stability, influencing investment decisions and market confidence.
Fri, 04 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Boston Scientific (BSX) closed at $84.54, marking an increase of 0.86% from the previous trading day.
Why It Matters - The 0.86% increase in Boston Scientific's stock price reflects positive market sentiment, which could indicate investor confidence and potential for future growth.
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Boston Scientific Corporation (NYSE: BSX) will host a webcast on October 23, 2024, at 8:00 a.m. to discuss Q3 financial results and a cardiology business update.
Why It Matters - The webcast will provide insights into Boston Scientific's Q3 financial performance and cardiology business developments, influencing investor sentiment and stock valuation.
Wed, 02 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - BSX's recent acquisitions have expanded its product offerings, indicating potential growth opportunities for the company.
Why It Matters - BSX's acquisitions enhance its product portfolio, signaling growth potential and competitive advantage, which could lead to increased revenue and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
